<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	xmlns:georss="http://www.georss.org/georss" xmlns:geo="http://www.w3.org/2003/01/geo/wgs84_pos#" xmlns:media="http://search.yahoo.com/mrss/"
	>

<channel>
	<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
	<atom:link href="http://prostatecancerinfolink.net/feed/" rel="self" type="application/rss+xml" />
	<link>http://prostatecancerinfolink.net</link>
	<description></description>
	<lastBuildDate>Tue, 14 Feb 2012 02:29:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.com/</generator>
<cloud domain='prostatecancerinfolink.net' port='80' path='/?rsscloud=notify' registerProcedure='' protocol='http-post' />
<image>
		<url>http://s2.wp.com/i/buttonw-com.png</url>
		<title>THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK</title>
		<link>http://prostatecancerinfolink.net</link>
	</image>
	<atom:link rel="search" type="application/opensearchdescription+xml" href="http://prostatecancerinfolink.net/osd.xml" title="THE &#34;NEW&#34;  PROSTATE CANCER INFOLINK" />
	<atom:link rel='hub' href='http://prostatecancerinfolink.net/?pushpress=hub'/>
		<item>
		<title>Years of life lost due to prostate cancer in the USA: 1972-2006</title>
		<link>http://prostatecancerinfolink.net/2012/02/13/years-of-life-lost-due-to-prostate-cancer-in-the-usa-1972-2006/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/13/years-of-life-lost-due-to-prostate-cancer-in-the-usa-1972-2006/#comments</comments>
		<pubDate>Mon, 13 Feb 2012 18:29:38 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[lost]]></category>
		<category><![CDATA[PYLL]]></category>
		<category><![CDATA[years]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15021</guid>
		<description><![CDATA[A new paper in this month&#8217;s Journal of Urology has attempted to document the potential number of years of life lost (PYLL) to prostate cancer (and other forms of urogenital cancer) between 1972 and 2006 &#8212; based on the Surveillance, Epidemiology and End Results (SEER) data. According to Kamel et al., the PYLL for prostate [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=15021&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/13/years-of-life-lost-due-to-prostate-cancer-in-the-usa-1972-2006/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>

		<media:content url="http://talkaboutprostatecancer.files.wordpress.com/2012/02/pyll-data1.png" medium="image">
			<media:title type="html">PYLL data</media:title>
		</media:content>
	</item>
		<item>
		<title>How am I meant to get THERE from HERE?</title>
		<link>http://prostatecancerinfolink.net/2012/02/11/how-am-i-meant-to-get-there-from-here/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/11/how-am-i-meant-to-get-there-from-here/#comments</comments>
		<pubDate>Sat, 11 Feb 2012 13:33:45 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[category]]></category>
		<category><![CDATA[distance]]></category>
		<category><![CDATA[race]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[urologist]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15009</guid>
		<description><![CDATA[A new report just published on line in the Journal of Urology has shown that &#8212; at least in the state of North Carolina &#8212; distance from the nearest urologist affects prostate cancer risk category at diagnosis and may disproportionately impact black as opposed to white patients. Holmes et al. examined data from the North [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=15009&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/11/how-am-i-meant-to-get-there-from-here/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Korean study says that HIFU &#8220;does not provide effective oncologic outcomes&#8221;</title>
		<link>http://prostatecancerinfolink.net/2012/02/10/korean-study-says-that-hifu-does-not-provide-effective-oncologic-outcomes/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/10/korean-study-says-that-hifu-does-not-provide-effective-oncologic-outcomes/#comments</comments>
		<pubDate>Fri, 10 Feb 2012 16:13:13 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[complications]]></category>
		<category><![CDATA[first line]]></category>
		<category><![CDATA[HIFU]]></category>
		<category><![CDATA[high-intensity focused ultrasound]]></category>
		<category><![CDATA[outcome]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=15007</guid>
		<description><![CDATA[A new paper by clinical researchers in Korea has concluded that treatment with high-intensity focused ultrasound (HIFU) &#8220;does not provide effective oncologic outcomes even in low risk patients with prostate cancer as well as in the intermediate or high risk groups,&#8221; but does have a low associated incidence of treatment complications. The value of HIFU [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=15007&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/10/korean-study-says-that-hifu-does-not-provide-effective-oncologic-outcomes/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>The potential of MVA-5T4 as treatment for advanced prostate cancer</title>
		<link>http://prostatecancerinfolink.net/2012/02/10/the-potential-of-mva-5t4-as-treatment-for-advanced-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/10/the-potential-of-mva-5t4-as-treatment-for-advanced-prostate-cancer/#comments</comments>
		<pubDate>Fri, 10 Feb 2012 15:28:31 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[castration-resistant]]></category>
		<category><![CDATA[mCRPC]]></category>
		<category><![CDATA[metastatic]]></category>
		<category><![CDATA[MVA-5T4]]></category>
		<category><![CDATA[TroVax]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14996</guid>
		<description><![CDATA[Early data have suggested that a modified vaccinia Ankara (MVA) virus that expresses a tumor-associated glycoprotein called 5T4 may have activity in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) &#8212; among other forms of cancer. We will refer to this agent as MVA-5T4; the brand name is TroVax®. Last year, a paper [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14996&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/10/the-potential-of-mva-5t4-as-treatment-for-advanced-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Problems with enrollment into ongoing Phase III trials of new drugs for men with mCRPC?</title>
		<link>http://prostatecancerinfolink.net/2012/02/09/problems-with-enrollment-into-ongoing-phase-iii-trials-of-new-drugs-for-men-with-mcrpc/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/09/problems-with-enrollment-into-ongoing-phase-iii-trials-of-new-drugs-for-men-with-mcrpc/#comments</comments>
		<pubDate>Thu, 09 Feb 2012 16:45:32 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[ipilimumab]]></category>
		<category><![CDATA[TAK-700]]></category>
		<category><![CDATA[tasquinimod]]></category>
		<category><![CDATA[trials]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14992</guid>
		<description><![CDATA[Has the clinical success of some new drugs started to affect enrollment in trials of others for advanced forms of prostate cancer? Back in November 2010, Millennium announced the initiation of two large, multi-center, randomized, double-blind, Phase III trials designed to test the effectiveness and safety of a drug known as TAK-700 (in combination with [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14992&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/09/problems-with-enrollment-into-ongoing-phase-iii-trials-of-new-drugs-for-men-with-mcrpc/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Does coronary artery disease increase risk for a diagnosis of prostate cancer?</title>
		<link>http://prostatecancerinfolink.net/2012/02/09/does-coronary-artery-disease-increase-risk-for-a-diagnosis-of-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/09/does-coronary-artery-disease-increase-risk-for-a-diagnosis-of-prostate-cancer/#comments</comments>
		<pubDate>Thu, 09 Feb 2012 14:39:36 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[coronary artery disease]]></category>
		<category><![CDATA[heart disease]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14989</guid>
		<description><![CDATA[A study just published on line in Cancer Epidemiology, Biomarkers &#38; Prevention has suggested (albeit not for the first time)  that a baseline history of coronary artery disease may be a meaningful risk factor for prostate cancer. The new paper by Thomas et al. is based on an analysis of data from the 4-year-long REDUCE [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14989&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/09/does-coronary-artery-disease-increase-risk-for-a-diagnosis-of-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Advisory panel does NOT recommend approval of Xgeva for prevention of bone mets</title>
		<link>http://prostatecancerinfolink.net/2012/02/08/advisory-panel-does-not-recommend-approval-of-xgeva-for-prevention-of-bone-mets/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/08/advisory-panel-does-not-recommend-approval-of-xgeva-for-prevention-of-bone-mets/#comments</comments>
		<pubDate>Wed, 08 Feb 2012 21:16:04 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[denosumab]]></category>
		<category><![CDATA[metastasis]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Xgeva]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14985</guid>
		<description><![CDATA[According to an online report in The Washington Post earlier this afternoon, an advisory panel to the U.S. Food and Drug Administration (FDA) has voted 12 to 1 not to recommend the approval of denosumab (Xgeva®) for the prevention of bone metastasis in men with non-metastatic, castrate-resistant prostate cancer. The advisory committee appears to have [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14985&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/08/advisory-panel-does-not-recommend-approval-of-xgeva-for-prevention-of-bone-mets/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Can high levels of dietary calcium lower risk for prostate cancer?</title>
		<link>http://prostatecancerinfolink.net/2012/02/08/can-high-levels-of-dietary-calcium-lower-risk-for-prostate-cancer/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/08/can-high-levels-of-dietary-calcium-lower-risk-for-prostate-cancer/#comments</comments>
		<pubDate>Wed, 08 Feb 2012 12:40:56 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Prevention]]></category>
		<category><![CDATA[calcium]]></category>
		<category><![CDATA[diet]]></category>
		<category><![CDATA[risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14980</guid>
		<description><![CDATA[Case-control studies based on data from self-reported questionnaires of people&#8217;s diets are rarely the most accurate predictors of reality. However, for what it is worth, a new study has reported that higher levels of calcium in a man&#8217;s normal diet may be associated with a lower risk for diagnosis of prostate cancer. Williams et al., [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14980&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/08/can-high-levels-of-dietary-calcium-lower-risk-for-prostate-cancer/feed/</wfw:commentRss>
		<slash:comments>4</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Occurrence of infections and hospitalizations in men having prostate biopsy (in Europe)</title>
		<link>http://prostatecancerinfolink.net/2012/02/07/occurrence-of-infections-and-hospitalizations-in-men-having-prostate-biopsy-in-europe/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/07/occurrence-of-infections-and-hospitalizations-in-men-having-prostate-biopsy-in-europe/#comments</comments>
		<pubDate>Tue, 07 Feb 2012 13:11:42 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Risk]]></category>
		<category><![CDATA[biopsy]]></category>
		<category><![CDATA[hospitalization]]></category>
		<category><![CDATA[infection]]></category>
		<category><![CDATA[risk]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14977</guid>
		<description><![CDATA[There has been increased discussion in the past couple of years related to the risk of infection in men undergoing prostate biopsy after initial testing for risk of prostate cancer (based on results of PSA test data and/or a digital rectal examination). Studies based on data from the United States and Canada have previously reported [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14977&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/07/occurrence-of-infections-and-hospitalizations-in-men-having-prostate-biopsy-in-europe/feed/</wfw:commentRss>
		<slash:comments>7</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Will denosumab gain approval for prevention of onset of metastasis to bone?</title>
		<link>http://prostatecancerinfolink.net/2012/02/06/will-densoumab-gain-approval-for-prevention-of-onset-of-metastasis-to-bone/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/06/will-densoumab-gain-approval-for-prevention-of-onset-of-metastasis-to-bone/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 21:22:19 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[bone]]></category>
		<category><![CDATA[denosumab]]></category>
		<category><![CDATA[metastasis]]></category>
		<category><![CDATA[Prevention]]></category>
		<category><![CDATA[Xgeva]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14972</guid>
		<description><![CDATA[The U.S. Food and Drug Administration (FDA) has questioned the value of denosumab (Xgeva®) as an agent capable of delaying the onset of metastatic disease to bone in men with progressive, castration-resistant prostate cancer. An FDA Advisory Committee will meet on Wednesday this week to discuss the application by Amgen for approval of denosumab as [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14972&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/06/will-densoumab-gain-approval-for-prevention-of-onset-of-metastasis-to-bone/feed/</wfw:commentRss>
		<slash:comments>7</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Long-term use of abiraterone acetate at 250 mg/d: is this really viable?</title>
		<link>http://prostatecancerinfolink.net/2012/02/06/long-term-use-of-abiraterone-acetate-at-250-mgd-is-this-really-viable/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/06/long-term-use-of-abiraterone-acetate-at-250-mgd-is-this-really-viable/#comments</comments>
		<pubDate>Mon, 06 Feb 2012 12:41:28 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[low-dose]]></category>
		<category><![CDATA[maintenance]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14960</guid>
		<description><![CDATA[It has been suggested that, after an initial &#8220;loading dose&#8221; for a period of time, abiraterone acetate could potentially be used to treat metastatic, castration-resistant prostate cancer (mCRPC) at a much lower daily maintenance dose than that currently approved. In two messages left on this site (on February 2 and on February 4, 2012), Prof. Gerry Potter (one [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14960&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/06/long-term-use-of-abiraterone-acetate-at-250-mgd-is-this-really-viable/feed/</wfw:commentRss>
		<slash:comments>10</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Other interesting presentations from the GU Oncology meeting: Part II</title>
		<link>http://prostatecancerinfolink.net/2012/02/05/other-interesting-presentations-from-the-gu-oncology-meeting-part-ii/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/05/other-interesting-presentations-from-the-gu-oncology-meeting-part-ii/#comments</comments>
		<pubDate>Sun, 05 Feb 2012 16:46:32 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Diagnosis]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14949</guid>
		<description><![CDATA[The following is promised commentary on a second group of the more interesting presentations last Thursday at the Genitourinary Cancer Symposium in San Francisco, with links to the more detailed abstracts. The majority of these presentations were posters as opposed to oral presentations. Lin et al. presented data suggesting that, for men initially placed on active [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14949&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/05/other-interesting-presentations-from-the-gu-oncology-meeting-part-ii/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Other interesting presentations from the GU Oncology meeting: Part I</title>
		<link>http://prostatecancerinfolink.net/2012/02/03/other-interesting-presentations-from-the-gu-oncology-meeting-part-i/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/03/other-interesting-presentations-from-the-gu-oncology-meeting-part-i/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 16:16:08 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14941</guid>
		<description><![CDATA[We promised to give a summary of other interesting prostate cancer-related data presented at the Genitourinary Cancer Symposium out in San Francisco. Here is an an initial commentary on some of the presentations that seemed (to us) to be of particular interest: Gray et al. offered new data suggesting that while the early side effects [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14941&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/03/other-interesting-presentations-from-the-gu-oncology-meeting-part-i/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>Educational updates from the GU Oncology Symposium</title>
		<link>http://prostatecancerinfolink.net/2012/02/03/educational-updates-from-the-gu-oncology-symposium/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/03/educational-updates-from-the-gu-oncology-symposium/#comments</comments>
		<pubDate>Fri, 03 Feb 2012 13:03:51 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Drugs in development]]></category>
		<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14934</guid>
		<description><![CDATA[One of the most useful elements introduced this year at the Genitourinary Cancer Symposium still ongoing in San Francisco is the summary papers from the educational reviews presented at the meeting. In the content that follows, we have provided direct links to all of the significant summary papers dealing with key issues in the management [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14934&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/03/educational-updates-from-the-gu-oncology-symposium/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
		<item>
		<title>NICE initially refuses to cover cost of abiraterone acetate for mCRPC</title>
		<link>http://prostatecancerinfolink.net/2012/02/02/nice-initially-refuses-to-cover-cost-of-abiraterone-acetate-for-mcrpc/</link>
		<comments>http://prostatecancerinfolink.net/2012/02/02/nice-initially-refuses-to-cover-cost-of-abiraterone-acetate-for-mcrpc/#comments</comments>
		<pubDate>Thu, 02 Feb 2012 14:11:01 +0000</pubDate>
		<dc:creator>Sitemaster</dc:creator>
				<category><![CDATA[Living with Prostate Cancer]]></category>
		<category><![CDATA[Management]]></category>
		<category><![CDATA[Treatment]]></category>
		<category><![CDATA[abiraterone]]></category>
		<category><![CDATA[cost]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Zytiga]]></category>

		<guid isPermaLink="false">http://prostatecancerinfolink.net/?p=14932</guid>
		<description><![CDATA[In an utterly unsurprising announcement from the UK, the National Institute for Clincial Excellence (NICE) has issued draft guidance in which it refuses to cover the proposed cost of abiraterone actetate. This draft guidance looks suspiciously like the first round in a negotiating process with the manufacturer of abiraterone acetate. Why? Because Andrew Dillon, NICE&#8217;s [...]<img alt="" border="0" src="http://stats.wordpress.com/b.gif?host=prostatecancerinfolink.net&amp;blog=3176292&amp;post=14932&amp;subd=talkaboutprostatecancer&amp;ref=&amp;feed=1" width="1" height="1" />]]></description>
		<wfw:commentRss>http://prostatecancerinfolink.net/2012/02/02/nice-initially-refuses-to-cover-cost-of-abiraterone-acetate-for-mcrpc/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
	
		<media:content url="" medium="image">
			<media:title type="html">imperativa</media:title>
		</media:content>
	</item>
	</channel>
</rss>
